Skip to main content

Laura Castillo Ribelles

Institutions of which they are part

Predoctoral researcher
Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT)
Vall Hebron Institut de Recerca

Laura Castillo Ribelles

Institutions of which they are part

Predoctoral researcher
Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT)
Vall Hebron Institut de Recerca

Projects

The Vall d’Hebron Iniciative for Parkinson associated to GBA (VHIP-GBA): from biospecimen collection to translational studies and therapies.

IP: Marta Martínez Vicente
Collaborators: José Antonio Arranz Amo, Jorge Hernández Vara, Eddie Pradas Gracia, Guillem Pintos Morell, Clara Carnicer Cáceres, Carles Lorenzo Bosquet, David Moreno Martinez, Jordi Riera Heredia, Daniela Samaniego Toro, Laura Castillo Ribelles, Daniela Samaniego Toro
Funding agency: Instituto de Salud Carlos III
Funding: 245932.5
Reference: PI20/00728
Duration: 01/01/2021 - 30/06/2025

Demencia mixta por Alzheimer y enfermedad cerebrovascular: un estudio clínico y experimental.

IP: Maria Pilar Delgado Martínez
Collaborators: Francesc Pujadas Navinés, Olga Maisterra Santos, Laura Castillo Ribelles, Carles Lorenzo Bosquet, Antonio Palasi Franco, Maria Belén Gutiérrez Iglesias, Jesús Pizarro Gonzálvez, Diana Liebana Gutierrez
Funding agency: Instituto de Salud Carlos III
Funding: 134310
Reference: PI19/00217
Duration: 01/01/2020 - 30/06/2024

Desarrollo de una nueva terapia de reemplazo enzimático basada en nanotecnología para la enfermedad de Parkinson: restablecimiento de la actividad glucocerebrosidasa lisosomal mediante nanoconjugación enzima-polímero de GBA (NANO-ERT).

IP: Marta Martínez Vicente
Collaborators: Eddie Pradas Gracia, David Moreno Martinez, Jordi Riera Heredia, José Antonio Arranz Amo, Maria Camprodon Gomez, Laura Castillo Ribelles, Clara Carnicer Cáceres
Funding agency: Fundación Banco Bilbao Vizcaya Argentaria
Funding: 124047.74
Reference: BBVA/INVESTIGACIO/MARTINEZ
Duration: 01/05/2020 - 30/07/2023

Related news

Docetaxel, carried by Soluplus, proved to be the most effective and least toxic combination to cross the blood-brain barrier and attack the tumour directly.

Based on the study led by VHIR, a clinical trial has been approved for patients with locally advanced pancreatic cancer.

Vall d'Hebron participates in a project to develop innovative microsampling technology, making blood collection more accessible and patient-centered.

Related professionals

Neus Salvadó Pérez

Neus Salvadó Pérez

Research technician
Neurovascular Diseases
Read more
Sara Belmonte Calderon

Sara Belmonte Calderon

Research technician
Neurodegenerative Diseases
Read more
Maria Arantza Dema Etxezarreta

Maria Arantza Dema Etxezarreta

Investigador/a Postdoc
Clinical Trials Management Unit
Clinical Research Development Directorate
Read more
Luisa Sofia Silva Alcoser

Luisa Sofia Silva Alcoser

Predoctoral researcher
Translational Molecular Pathology
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.